Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -194.2%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $879209 | $2M | $206550 | $178388 | $7M | $22M | — | — |
| Enterprise Value | $-6642769 | $-5373213 | $-2955020 | $-7259747 | $538225 | $11M | — | — |
| P/E Ratio → | -0.16 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.19 | 0.35 | 0.13 | 0.03 | 1.13 | 2.15 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -194.2% | -194.2% | -310.4% | -126.0% | -119.2% | -228.1% | — | — |
| ROA | -132.6% | -132.6% | -213.5% | -104.5% | -103.5% | -129.2% | -242.3% | -228.5% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | -199.7% | -199.7% | -316.1% | -130.0% | -120.0% | -226.8% | — | -1303.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.21 | -2.03 | -1.17 | -1.04 | -1.07 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -151.18 | -172.25 | -15.41 | -17.83 |
Net cash position: cash ($8M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.79 | 4.79 | 1.79 | 4.91 | 7.53 | 7.66 | 0.16 | 1.20 |
| Quick Ratio | 4.79 | 4.79 | 1.79 | 4.91 | 7.53 | 7.66 | 0.16 | 1.20 |
| Cash Ratio | 4.59 | 4.59 | 1.60 | 4.58 | 6.76 | 7.12 | 0.14 | 1.16 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.4% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.4% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $926192 | $153000 | $19496 | $69066 | $52053 | $3470 | $3470 |
Clinical trial funding shortfall
Based on reported figures, DRMA trades at a P/B ratio of 0.19, which suggests that the market assigns minimal value to the company's intellectual property and clinical assets compared to its historical book value, reflecting deep skepticism regarding the firm's ability to achieve commercialization without further dilutive capital raises.
The extremely low P/B multiple indicates that investors are pricing in a high probability of continued value erosion rather than future clinical success. This valuation level is consistent with a firm that has exhausted its internal capital and is now trading primarily as a speculative option on its remaining cash and pipeline potential.
As reported in financial statements, the company's ROE has remained consistently negative, fluctuating between -26.3% and -100.0% over the last ten quarters, which highlights the structural inability of the current R&D-heavy business model to generate any return on invested capital prior to achieving regulatory approval.
The absence of positive ROIC or ROE is expected for a pre-revenue biotech, but the volatility in these metrics suggests that the company's capital base is being consumed rapidly by clinical trial expenses. Investors should monitor whether the company can stabilize these returns as it moves into the more capital-intensive Phase 3 development stage.
According to recent SEC filings, the current ratio of 7.09 appears robust on the surface, yet this figure is misleading because it reflects a lack of significant short-term liabilities rather than a strong cash position, leaving the company vulnerable to sudden liquidity shocks as clinical expenses continue to mount.
While the current ratio suggests a comfortable buffer, the absolute cash balance of $7.5 million is insufficient to support long-term Phase 3 operations. The liquidity profile is therefore fragile, as the company lacks the operational cash flow to replenish its current assets, making it entirely dependent on external financing.
Based on the provided financial data, the current ratio is the most commonly misapplied metric for DRMA, as it obscures the company's true operational runway by ignoring the high, non-discretionary nature of clinical trial costs that will inevitably deplete current assets in the near term.
Analysts should instead focus on the 'cash burn rate' relative to the remaining cash balance, as traditional liquidity ratios fail to account for the 'valley of death' inherent in clinical-stage biotech. Relying on the current ratio provides a false sense of security that ignores the company's structural dependence on dilutive equity markets.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DRMA stock.
Dermata Therapeutics, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Dermata Therapeutics, Inc.'s return on equity (ROE) is -194.2%. The historical average is -195.6%.
Based on historical data, Dermata Therapeutics, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.